



ATTORNEY DOCKET GC22.4-CON2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James Rasmussen et al.
Serial Number: 10/814,025
Filing Date: March 31, 2004
Title: ENZYMATICALLY ACTIVE RECOMBINANT
GLUCOCEREBROSIDASE

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY "EXPRESS MAIL"


The undersigned hereby certifies that the correspondence listed below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service, postage prepaid, in an envelope addressed to: Commissioner for Patents, Mail Stop Missing Parts, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

1. Transmittal Letter (1 page with duplicate);
2. Amendment in Response to Notice Under 37 CFR §§ 1.821-1.825 with copy of Notice to Comply (6 pages with duplicate);
3. Statement to Support Filing and Submission in Accordance with 37 CFR §§ 1.821-1.825 with attached Sequence Listing (3 pages);
4. A computer readable copy of the Sequence Listing (1 diskette).

All under Express Mail Label No. EV 386751625 US.

Dated of Deposit: August 4, 2004

Deborah A. Gunkel
Deborah A. Gunkel



8/05/04

FW

TRANSMITTAL LETTER (General - Patent Pending)	Docket No. GC22.4-CON2
---	---------------------------

In Re Application Of: Rasmussen et al.

Application No. 10/814,025	Filing Date March 31, 2004	Examiner Not Yet Assigned	Customer No. 24536	Group Art Unit 3747	Confirmation No. 4968
-------------------------------	-------------------------------	------------------------------	-----------------------	------------------------	--------------------------

Title: ENZYMATICALLY ACTIVE RECOMBINANT GLUCOCEREBROSIDASE

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Amendment in Response to Notice Under 37 CFR 1.821-1.825 with copy of Notice to Comply
Electronic and paper version of Sequence Listing
Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825
Certificate of Mailing by "Express Mail"

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 07-1074 as described below.
 - ☐ Charge the amount of _____
 - ☒ Credit any overpayment.
 - ☒ Charge any additional fee required.


Signature

Dated: August 4, 2004

Jennifer L. Dupre
Reg. No. 41,722
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
Tel. (617) 768-6523
Fax (617) 252-7553

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Signature of Person Mailing Correspondence
Typed or Printed Name of Person Mailing Correspondence

CC:




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/814,025	03/31/2004	James Rasmussen	GC22.4CON2

24536
 GENZYME CORPORATION
 LEGAL DEPARTMENT
 15 PLEASANT ST CONNECTOR
 FRAMINGHAM, MA 01701-9322



CONFIRMATION NO. 4968

FORMALITIES LETTER



OC000000012979407

Date Mailed: 06/17/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450

Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in dark ink, appearing to be 'Alan', written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY